首页|Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin,a novel humanized anti-HER2 antibody-drug conjugate therapy

Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin,a novel humanized anti-HER2 antibody-drug conjugate therapy

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据

Jia Jia、Lili Mao、Jing Lin、Wenyu Li、Pei Yuan、Lei Guo、Jie Dai、Caili Li、Xue Bai、Zhongwu Li、Yu Chen、Jun Guo、Jianming Ying、Lu Si

展开 >

State Key Laboratory of Molecular Oncology,Department of Pathology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China

Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Melanoma and Sarcoma,Peking University Cancer Hospital & Institute,Beijing 100142,China

Department of Medical Oncology,Clinical Oncology School of Fujian Medical University,Fujian Cancer Hospital,Fuzhou 350014,China

Department of Pathology,Peking University Cancer Hospital & Institute,Beijing 100142,China

展开 >

Beijing Medical Award FoundationBeijing Municipal Administration of Hospitals'Ascent PlanBeijing Xisike Clinical Oncology Research FoundationBeijing Xisike Clinical Oncology Research Foundation

YXJL-2020-0889-0106DFL20220901Y-Roche2019/2-0076Y-SY201901-0270

2024

10.1007/s11684-023-1046-2

医学前沿
高等教育出版社

医学前沿

CSTPCD
影响因子：1.362
ISSN：2095-0217
年,卷(期)：2024.18(3)